Abstracts Vol. 1 [International Conference on AIDS (11th: 1996: Vancouver, Canada)]

We.A.30 2, We.A.3056, We A.382,
We.A403, We.B 3346
cellular differentiation
Mo.A.1039, No.A.104C, [u.A.382,
We.B.3302
cellular immunity
Mo.A. 100, Mo.A. I 117. Mo.A. 15I
Mo.A.382, No.A.394, H A.5)i,
[h.A. 101, [h.A. 102, [h.13 4310, Th.F.4325,
Tu.A.28,3u.A.285 Tu.A.507, lu 132251,
We.A.283, We.A.3029, WA.3034,
We.A.3059, We A.3066, We.A.306 7,
We.A.3080,We A.382,We A.390,
We.A.4 33
censorship
N 0..1438, We.L.3854
central nervous system
Mo.B.123, H.1.1264, MoB 268,
Mo.B.1307, Mo.B. 1363, Mo.B 31 0,
Mo.B3 3, Pub. 13 1062,. Yh.A40414,
I.A.4062, TO A.40 /2,,T[ A.40 72,
Th.B. 181, [h B1I82, TO.13183, Tlh.0.184,
Th. B. 186, Th. B.42 18, Th..47223,
T.B.4225, T.1.4228, [h.B.4229,
Th.B.4232,TO [.4256,-1 h 1.425/,
Tu.A.20 I 3,Tu.1.22 I,Tu.B.22601,
Tu.B.2263,To.B.2264, Tu.3. 268,
Tu.B.2269,T.3 2278, Tu.1.2306,
Tu.B.2325, We.A. 145, We A 31 o8,
We.1.32 II, We.B.323 1, We.13 782,
We.B.3285, We.1.3286, We B.3289,
We.B.3290, We13 3291 WeB 3363
cerebrospinal fluid (CSF)
No..1 140, No.. 1231I, Mo.B.1232,
No.3.3 10, No.1.31 1, Mo.B3 314,
Pub.A. I 006,TOh.A.4078, Th..181,
Th 13 I182,.T[.1I85Th 1.4 70,TO.1.4223,
Tu.A. I154, Tu. B.2 I 95, Tu. B.2266, Tu.B 2306.
Tu.1.235/, We.A.3046, We.A.3 108.
We.1.3283, We.B.3285, Wo1.328/
cervical dysplasia/neoplasia
Mo.A. 142, PuO.B 1047 Th 13.115,
T h.B.l116, Th.B.4 3 2,3h. B.41 33.
T.B.4134.Th.13.4 35,..41 7,
Th.B.4138. 1-1134139, [0.8.4140,
[h. B.4 141,ITO1.4 142,1h.134168,
lu.1.2255,Tu.1.2256, T.C.2459,
bu.C 261 8, We.1.32/5, We.13 3276,
We.13 3277, We.B.32/3, We 1.3 21[,
We.B.54 1, We 1.542, We.B.543,
We.8B.544, We. B.545, We..3405,
N0.C 3412
cervicovaginal virus secretion
Tu.C.2466, [u.C.443, We.B. 19,
We..327/, We.C.330, WeC 33,
We.C332, We.C 333
Chagas disease (T. Cruzii)
PuO.B. I058,Th.B.42 18, Tu.1.22 II
chemotaxis
Pu.D. 1486,luAS50l
chemotherapy
No.A. 1020, No A. 1060, Mo.A 1063,
Mo.A. 108 I, N DA.10135, No.13.1240,
Mo.1.1250, Mo1..1254, M 1.1291,
Mo.8B.1292,. [hA 40 /7/Th AdO!79
16.13. 184,Th.13.4 165,3T1.8.4225,
Th.1.42 27, 1.A 261, [u.1.2223,

We.13306, WeB1331 3, We.1.3325,
We.B33326, WeBA20, We C.14 33,

We.0.3435. We.C.3440
children, development
No.0 1493, Pub.D. 1354, (6.1.4249,
3 h.D.4865,TO.D.487 I,Tu.B.23 12,
We.13.3 13, We.C.3442, We.0.3444,
WeD. 130
children, diagnosis
No.1 1/5, No.1.130/, N DB 1320,
No.0.1461, Pu.B. 10/9, P1).1.1080,
Pu b.D.1I48 6, Th. B.42/6, TI) 134 317,
Tu.B 2305, Tu.B 231 3,Tu.B.23 I4.
[u.0 2S99, [u.D.2773, We.13 301
We.13 31 4,We.13.3 I174, We 1.3176,
We.1331/9, We.C.3446, We.D.3842
children, foster care
No.0 I1460, Put.B. I074 PuL D. 1346,
Pub.D. 1355, [1..4758,1T h.[.4868,
[h.D.4883,.[D.4884,Th.1.4885,
3.D.4888, Tu.D.293/, We.B.3 151I
children, group care
NoD) 1766, Pub.B.1074. T.D.486/,
Tu.D,2 /46, We.3.31I5 I, We [3.3 /03
children, haemophilia
No.13 I 320,Tu.C.2633
children, immunological
No.13. 1353, Pub.B. I 075,Th.A. I160.
Iu.A.201I0, Tu.A.2096,Tu.B.225 I,
3u.1.23 I 8,Tu.B.23 70, We.A 3076,
We.A.3093, We.13.3 I0, We.13.3 I 1,
We.1.3324, We.1.3328, We.0 3448
children, neonates
Nc 1.1312, No.13.131 5, No.1I323,
Pu[.0.1 285, T 4.C 1 0, T.C 4/S5I,
[10.2480, Tu.0 2582, Tu.C.2606,
Iu.0.260/, We.A. 144. We.3. 105
children, neurological
No 1.1 305, No.3. 1 30/7,Tu 132306,
01.1.23 17,Tu.0.2576, We 133207,
We.1.3290, We.C 3442
children, orphans
No.[1. 1/62, Pub..1.I074, Pub6C. 1137,
PuO.3. 1339, Pub.D. I1345, PuoOD. I1346.
131.13. 1349. PoOID. 1350, PuO.D. 1353,
PO.13. 1354. P1)b [3.1355,. PoOD. 1422.
PAb.D 148 1, T..483/,TO.D.4861
T.[.4864Th.D.486/, TO.[.487 I,
T1 D.48 73, TO[.48/4,..4881
Th.D.4882. 3 h.D.4883, Th.D.4884,
[F.[34885,TO.D4889, Th.[3.4896.
16 D5066, Tu.A.20/2, Tu.1B.2 316.
Tu.C.203, fu.D 2753,Tu.D.2/73,Tu.D.485,
We. D. 133, We.D.363, We.D.3802
children, other
No13 1317, No.B.553. No.0.141 1,
PuO.D. 308. Pu.D. 1352, Th.13402,
T.B.432 I,Th.1.4326, 70.1.4342,
T.0 4426,T..4790,Th.C.4/91
[60 C4836,[u.B. I193, Tu.1.2250,01.1.2 3 0,
Tu.13 23 17,Tu.1.236/, [CoO 2461,
Tu.0 2604j u.0.2633, [u.L3462,
We.1.3267, We.0.3445, We.0.3449,
We.D.13, We.[3.135, We.D3605,
We.[2 3634. We.[3.3724, We.D.3/4
children, pathology
N.13 1307, No.13. 131 8, Pu1613. 1075,
BuL.B. I0/6 Puoh.1.079, Yh.A.4083,
T.B.4278. We.1.553

No 7.1.I347, PoO.B. I 079,TOh.1B.4295,
[[.13.43 17,Tu 1.1 93,Tu.B3 2202, To 1.224 I,

Tu.B.2296, Tu.B.23 I I,Tu.B 231 4,
Tu1.2315, We.33 I, We.[1313,
We.B.3 I15, We.B.3 125, We,1.553,
We.0.3439, We.0.3440, We.0.3444
children, progression
No.1.1308, No.132,2, M(..13753,
No.6 1404,NMo.C.1493,NMo.D. 8/3,
PuL.B.1I084, Th. A. 160, [1.1.31 8,
31 1.4321I.T.B.4338,Tu A.2096,
[u.B.227/ Tu.1.23(9,Tu.B.23 14,
l U.1 B231 5,lu.B.2 31I8, Tu. B.2320,
ToO.258 1,We.A.3093, No.13.3 10,
We.B 311I,We.13.31I3, We.13.3304,
We.1.3326, We.B.3338. We.B.552,
We.C.3433, We C.3436, We.C.3437,
We 0.3438, We.C.3439, We.0 3440,
We.C.344 I, We.C.3444, We.C.3448,
We.C.3449, We.C.346 I, We.C.3473
children, psychology
No.13 I '13, No.0. I1873, PCAD. 347,
3113 41365,3.D42613 30D.481
We. B3 312
children, sexual abuse
No.D 7 18,Pub.OI13,[u00.22,
Tu. B.2 3 1/, Tu.C. 268 3, Tu.D. 13 6,
01.1.27 4, Tu.D.2807
children, social impact
NoD 372, PubOB. 1075, Poib.B. 0/8,
Po.. 2o7, Puu.[3. I290, PuLLO.1I 9o,
PAI.D. 1346, Pub.[3.1I348, PuO.D. 1353,
T.ID.486 I, [.D.4862, [6 D.4863,
Thl D.4865,3-.D.487 I,TO.D 4881,
[.D.4B83,T.D.4885 T.D.4886,
TI.D4901,T.D505 I Tu B.2309,
T.,.D.2.3, [u. D.46 2,We. 0. 130.'WeD )1
We.D.363, We.D.375
children, treatment
NoA 1097. No.A. I109, No.B. 1293,
No.1.1306,NMo.B 1314,N.1.1315,
No.1.1319, No.D. 177/, No.D. 18/3,
TO.B.4 I 03,TO.B.4344,TO.B.4353,
[11I..4/29,-[.D. 255,TO.ID.486 I.
3T.D SI 2 I, u.B.23O8, 10.1.231 7,
Tu. 1.2370,Tu.D.2/46. We.13.3323,
We BS I, We.C 3433. Vee C. 3444,
We.C.344 /
children, twins
30.B.134I,Tu..z46,.I.D2882
children, vaccination
(133D.202
Chinese medicinal herbs
No.A. I1099, N..B.303,T.13.4 QD,
Th.134 104, T.1.4109 T[.D.,5I16(
We.13195
chlamydia trachomatis
No.0.1I61I4, No.0.1I61I7, No.0.341
No.0.440, PuO.B. 1046, Pub C. 12136,
1OhC.474 I,TO.C 4756,Tu.B.2 145,
We.AI.,Wo.B.3188
ciprofloxacin
No.. 1369, No.3. 1 372, Tu.B.2328,
We.B 3226, We.B.329/
circumcision
1u.D I 294,Tu.C.2686, We.C.22 I
civil rights
No.13550, Y.D.486 1,11.13.49/8.
[11 D.SOI13, Wo.ID.3646, We D.365 I,

T0.13.41 86, Th. B.4209,30 h B.42 36,
3.B.4290,T.O:.459/ 11)13B.2129,

3.B.2 144. [u 1.2191), Pu B 222/.
Tu.B.2242 Tu.13 2251. (u13 23D4,
To 1.23 1 I1IT.B.2320, 1DB 2358,
[6.B.233, Ti.B310 b13._.I IWe. 133224,
We.13 325, We. B.3282,VWe.1.3 333,
V/e.348, We.B 731 VWl 0 771,
We 0.3409
clinical trials, ethics
N.B1206,.0.1587,.0.1591.
[0 B.4144, 1.D494 1,11.1.2142,
To.B52O, Tu.13.52 3,WeC.2 12,We. D.I13[I
clinical trials, methodology
Nu.B 1253 N oB13 /6 O.1 392.
N.B290,N o.0 58,. 01592,
No 0.1594, N.0.153% N o..196,
T.A403 1,T[.B.4 (4, 1 B 4 4.
1113'[146,17.11 110T.B.13483.
3B 13B.4296, To 0.2 3,31 1 324,
[0.0.4626,3.B137,To B I/3, Iu.B/74,
[013 2190,TB2340T.B.,3/5,b1131052,
[.3 233 T.C.259, T10.444,
We.B.3136, WeBD 61.1veeB.3162,
We.B.3I65, We3.D166L.We.B. 176.
WOC2IIVWeC22,Ae0C21'
clinical trials, other
No.1 121, M.B132.Mo.B 138.
No 1.1 145, N 713.1359, N 1.29.1,
N.B300. 041 1.No.B432,
No..iO, N.0.143 Pou1.B u58.
3613 11 T.3171 h.B. 3290,311.13.4097.
T.B.4098 13 13I0,.B41 1 1.
1 1.4 143, 16.1.4 145,1 B4 46,
3.B,414/.31hB.4 88110.4337,
T.B 4354, TO.C.32 IflI..41l?
1-I.C.438, h[D585. [oB 71,711.133
11).B.1/5,TloB. 183, Tu.B.2 [1T.0.2 20.
3.B2 1 23.bo 132215,3)0.2220.
lo.B 22/43DuB 221'63T 11322/,
b1.1.2286,booB 2308. 1.3.2318,
Tu. B.2350, Tu. B.235 8 Tu. 13.411 11113 '[,3,
7u.[D.294, We.A.273 AWe.B.2o
We.B.3125. We.13 3 2/,V/e.B 3129.
We.Bb 58. WeBb 153.We.B.362,
We.B.3 I164. We.B.3 160, We B. 320,
We 13, 3293. We 1.423
clinical trials, support
No.. 1588,PB.PA h460.1T.14 40
[[0C320.1 1 5,S. (35 44
TO.D.S 8 1013u.1 '2.1113.173.1110..2312,
We.B.3160V1/e. B316o2,VWe1B33365.
We D3/24
clinical trials, vaccines
No, All17, MoA. 1, A283
N.A.287 N oA.284, MoA 105.
Mo.A.406, N C B' 11 o.C1588.
No.0 1S90, Ml.1 1I,01.0. 502,
1 hA.4039,T[..17/4, Tu A.2 102 To A 2 7'4.
11.8. 7/2,We.A3079,V/e.B 1,
We.B293, WeBz94, We.B 302,
We.B337" AeON 3;2 73/cO /30.,
We.0.211 WeC.2I1, We 2.12.
WeC. 213.We.C.2 4. We.0 2 5,
We.C. 3532, We 0.460
clotting factors
011.1 264,.M.13 1294
CMV, SEE cytomegalovirus
01 A. 11/07..1243(1 B3 I

We 0.34 9 We.C342 0,We C 3450,
We 0.3[o 3

a)
0
C
0
0Q
C
0
(1)
C
a.)
C
0
U
C
0
0
C
a)
479